People · Operator
Named in public records as an officer, director or promoter · active 2011–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| IntegenX Inc | — | Biotechnology | Series C | $133.9M | $2.0B | 2011 |
| S2 Genomics, Inc. | — | Biotechnology | Seed | $4.4M | $64.6M | 2019 |
Stevan Jovanovich at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stevan Jovanovich on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David S Smith | 1 | 12 |
| PETER WAGNER | 1 | 11 |
| James C. Blair | 1 | 8 |
| Michael Finney | 1 | 6 |
| David C. Barker | 1 | 4 |
| Benjamin S. Schapiro | 1 | 4 |
| Michael Wiley | 1 | 4 |
| Ronald W. Eastman | 1 | 2 |
| James N. Woody, M.D., Ph.D | 1 | 2 |
| Roger McIntosh | 1 | 1 |
| Dennis C. Harris | 1 | 1 |
| Louis C. Grever | 1 | 1 |
| Andre C. Marion | 1 | 1 |
| Mostafa C. Ronaghi | 1 | 1 |
| Dong-Su C. Kim | 1 | 1 |
| Shannon Hall | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.